Early Local Tumour Control and Feasibility of Intratumoral P-32 Microparticle Implantation in Patients with Locally Advanced Pancreatic Cancer: A Prospective Single-Center Observational Cohort Study

Le résumé fourni par la source

Background: Pancreatic cancer is a leading cause of cancer-related mortality. Locally advanced pancreatic cancer (LAPC) remains associated with low resection rates and poor survival despite advances in systemic therapy. Intratumoral Phosphorus-32 (P-32) microparticle implantation is an emerging locoregional brachytherapy approach for unresectable LAPC. Methods: This prospective single-center observational cohort study included patients with unresectable LAPC treated with gemcitabine plus nab-paclitaxel and EUS-guided intratumoral P-32 microparticle implantation. Intratumoral distribution was assessed by SPECT/CT. Tumour response was evaluated according to RECIST 1.1, with local disease control rate (LDCR) assessed at approximately 16 weeks. Adverse events were graded according to CTCAE version 4.0. Results: Seventeen patients underwent P-32 implantation (median age, 70 years; ECOG PS 0–1). SPECT/CT confirmed appropriate intratumoral distribution in all patients, with no implantation-related procedural complications. At 16 weeks, 7/16 evaluable patients (43.8%) achieved partial response and 9/16 (56.2%) had stable disease, resulting in an LDCR of 100% among evaluable patients and 94.1% in the all-treated analysis. Mean target-lesion diameter decreased from 3.4 to 2.8 cm, with a median reduction of 21.4%. CA19-9 decreased by ≥50% in 13/16 evaluable patients (81.2%). Four patients (23.5%) underwent surgical resection, all achieving R0 resection. Adverse events were predominantly grade 1–2; one grade 3 event and no grade 4–5 events occurred. Conclusions: P-32 microparticle implantation combined with systemic chemotherapy was feasible and demonstrated encouraging early local activity with an acceptable safety profile. These findings support further prospective evaluation in larger cohorts.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.